Dilarof Tablet 500 mcg contains Roflumilast 500 mcg, a selective phosphodiesterase-4 (PDE4) inhibitor used primarily in the management of chronic obstructive pulmonary disease (COPD). Roflumilast helps reduce inflammation in the airways, thereby decreasing the frequency of exacerbations and improving respiratory function in patients with severe COPD associated with chronic bronchitis.

Chronic obstructive pulmonary disease is a progressive lung disorder characterized by airflow limitation, chronic inflammation, and frequent exacerbations. Exacerbations can significantly reduce quality of life, lead to hospitalization, and accelerate disease progression. Dilarof Tablet 500 mcg works by targeting the inflammatory pathways responsible for airway narrowing, mucus production, and tissue damage, helping patients maintain better lung function and daily activity levels.

Unlike bronchodilators, roflumilast does not directly relax airway muscles but instead addresses the underlying inflammation, complementing other COPD therapies such as inhaled corticosteroids and long-acting bronchodilators. The oral tablet formulation allows convenient once-daily dosing, ensuring steady therapeutic effects and adherence.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Dilarof Tablet 500 mcg is indicated for:

• Reduction of exacerbations in severe COPD patients with chronic bronchitis

• Management of COPD symptoms in patients with a history of frequent flare-ups

• Adjunctive therapy for patients already receiving long-acting bronchodilators or inhaled corticosteroids

• Patients at risk of progressive lung function decline due to chronic inflammation

Key Benefits

• Reduces airway inflammation and prevents COPD exacerbations

• Improves respiratory function and quality of life

• Supports long-term management of chronic bronchitis-related COPD

• Convenient oral once-daily dosing enhances adherence

• Can be used alongside other COPD medications for comprehensive treatment

Mechanism of Action

Roflumilast, the active ingredient in Dilarof Tablet, is a selective PDE4 inhibitor. PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a molecule that regulates inflammation in the lungs. By inhibiting PDE4, roflumilast increases intracellular cAMP levels, which suppresses the release of pro-inflammatory mediators such as cytokines and chemokines. This reduces inflammation, airway narrowing, and mucus production, helping prevent COPD exacerbations and maintain better lung function.

Dosage and Administration

• The recommended dose is 500 mcg orally once daily, preferably at the same time each day.

• Tablets can be taken with or without food.

• Swallow the tablet whole with water; do not crush or chew.

• Regular daily administration is crucial for optimal control of symptoms and reduction of flare-ups.

• Dose adjustments may be required for patients with severe liver impairment; use is not recommended in moderate to severe liver disease without medical supervision.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Not recommended for patients with moderate to severe liver impairment.

• Use cautiously in patients with weight loss, depression, or a history of psychiatric disorders, as roflumilast may exacerbate these conditions.

• Monitor for gastrointestinal symptoms, weight loss, or mood changes during therapy.

• Inform your physician of all concomitant medications to avoid potential drug interactions.

Possible Side Effects

Dilarof Tablet 500 mcg is generally well tolerated, though some side effects may occur:

• Diarrhea or abdominal discomfort

• Nausea

• Headache

• Weight loss

• Rarely, insomnia or mood changes

Most side effects are mild and temporary; dose adjustments or supportive care may help minimize adverse effects.

Storage

Store below 30°C in a dry, cool place, away from direct light and moisture. Keep out of reach of children.